Total Payments
$1.7M
2024 Payments
$349,312
Companies
48
Transactions
1,893
Medicare Patients
51
Medicare Billing
$1,992
Payment Breakdown by Category
Other$1.1M (63.0%)
Consulting$428,076 (25.3%)
Travel$121,802 (7.2%)
Food & Beverage$44,221 (2.6%)
Research$22,742 (1.3%)
Education$10,235 (0.6%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $913,413 | 235 | 54.0% |
| Consulting Fee | $428,076 | 197 | 25.3% |
| Travel and Lodging | $121,802 | 614 | 7.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $79,500 | 22 | 4.7% |
| Honoraria | $72,981 | 34 | 4.3% |
| Food and Beverage | $44,221 | 773 | 2.6% |
| Unspecified | $22,742 | 12 | 1.3% |
| Education | $10,235 | 5 | 0.6% |
| Gift | $19.40 | 1 | 0.0% |
Payments by Type
General
$1.7M
1,881 transactions
Research
$22,742
5 transactions
Ownership
$0
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $477,018 | 774 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $194,119 | 108 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $146,149 | 185 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $140,154 | 155 | $0 (2024) |
| Oyster Point Pharma, Inc. | $103,594 | 118 | $0 (2024) |
| Lumenis Ltd. | $102,391 | 13 | $0 (2021) |
| Lumenis BE inc | $78,790 | 5 | $0 (2024) |
| Tarsus Pharmaceuticals, Inc. | $75,310 | 48 | $0 (2024) |
| Alcon Vision LLC | $71,281 | 59 | $0 (2024) |
| ABBVIE INC. | $61,072 | 68 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $349,312 | 275 | Bausch & Lomb Americas Inc. ($89,449) |
| 2023 | $192,815 | 207 | Bausch & Lomb Americas Inc. ($47,116) |
| 2022 | $295,623 | 276 | Mallinckrodt Hospital Products Inc. ($65,461) |
| 2021 | $205,472 | 163 | Allergan, Inc. ($84,658) |
| 2020 | $115,646 | 127 | Allergan, Inc. ($36,880) |
| 2019 | $201,478 | 302 | Allergan Inc. ($87,536) |
| 2018 | $174,677 | 280 | Allergan Inc. ($70,053) |
| 2017 | $157,967 | 263 | Allergan Inc. ($139,596) |
All Payment Transactions
1,893 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Nordic Pharma, Inc. | Lacrifill (Device) | Consulting Fee | Cash or cash equivalent | $5,642.80 | General |
| Category: Opthalmics | ||||||
| 12/24/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,800.00 | General |
| Category: Ophthalmology | ||||||
| 12/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Ophthalmology | ||||||
| 12/19/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,395.00 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/17/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Ophthalmology | ||||||
| 12/13/2024 | Amgen Inc. | TEPEZZA (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | BLINK NUTRITEARS (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/10/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,720.00 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/10/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $100.20 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 12/07/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug), Xelpros | Food and Beverage | In-kind items and services | $95.69 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Dompe US, Inc. | OXERVATE (Drug) | Food and Beverage | In-kind items and services | $119.61 | General |
| Category: SOLUTION/ DROPS | ||||||
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $123.88 | General |
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $312.20 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $103.78 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $27.92 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $21.44 | General |
| Category: Ophthalmology | ||||||
| 11/26/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: Ophthalmology | ||||||
| 11/22/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $692.94 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $122.85 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction (Mojave Study) | Bausch Health US, LLC | $13,800 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,275 | 1 |
| Fellow Eye | Oyster Point Pharma, Inc. | $1,667 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 4 | 51 | 85 | $5,855 | $1,992 |
Total Patients
51
Total Services
85
Medicare Billing
$1,992
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 12 | $2,890 | $788.88 | 27.3% |
| 83861 | Microfluid analysis of tears | Office | 2020 | 14 | 30 | $1,350 | $660.90 | 49.0% |
| 83516 | Analysis of substance using immunoassay technique | Office | 2020 | 13 | 26 | $741.00 | $293.80 | 39.6% |
| 92285 | Photography of content of eyes | Office | 2020 | 13 | 17 | $873.80 | $248.46 | 28.4% |
About Dr. Laura Periman, MD
Dr. Laura Periman, MD is a Cornea and External Diseases Specialist healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1376755009.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laura Periman, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $349,312 received in 2024. These payments were reported across 1,893 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($913,413).
As a Medicare-enrolled provider, Periman has provided services to 51 Medicare beneficiaries, totaling 85 services with total Medicare billing of $1,992. Data is available for 1 year (2020–2020), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Cornea and External Diseases Specialist
- Other Specialties Ophthalmology
- Location Seattle, WA
- Active Since 05/04/2007
- Last Updated 04/19/2023
- Taxonomy Code 207WX0120X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1376755009
Products in Payments
- RESTASIS (Drug) $214,763
- ACTHAR (Biological) $195,756
- TYRVAYA (Drug) $101,927
- VUITY (Drug) $98,168
- MIEBO (Drug) $90,470
- XIIDRA (Drug) $83,965
- Cequa (Drug) $83,289
- RESTASIS MULTIDOSE (Drug) $67,161
- CEQUA (Drug) $53,471
- M22 (Device) $40,916
- Systane (Drug) $33,950
- TearCare (Device) $32,023
- XDEMVY (Drug) $30,858
- EYSUVIS (Drug) $23,292
- Lumenis Pulse 120H (Device) $17,791
- ILUX (Device) $17,599
- optilight (Device) $16,632
- OPTILIGHT (Device) $15,000
- TEPEZZA (Drug) $9,619
- CEQUA (cyclosporine ophthalmic solution) 0.09% (Drug) $7,456
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.